2006
DOI: 10.1001/archderm.142.8.1031
|View full text |Cite
|
Sign up to set email alerts
|

Wilms Tumor 1 Expression Present in Most Melanomas but Nearly Absent in Nevi

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
21
3

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(29 citation statements)
references
References 15 publications
5
21
3
Order By: Relevance
“…IHC staining for Wilms tumor protein in melanomas and the lack of staining in nevi had demonstrated utility in distinguishing melanomas from nevi. 24 In that study, which used cutoff points similar to those in the current study, Wilms tumor protein exhibited a positive predictive value of 92.6% and a negative predictive value of 51.0%, values less robust than those of p15. Despite this difference, it would be interesting to determine whether analyses of p15 and Wilms tumor protein together would provide added benefit over the use of either marker alone.…”
Section: Discussionmentioning
confidence: 50%
“…IHC staining for Wilms tumor protein in melanomas and the lack of staining in nevi had demonstrated utility in distinguishing melanomas from nevi. 24 In that study, which used cutoff points similar to those in the current study, Wilms tumor protein exhibited a positive predictive value of 92.6% and a negative predictive value of 51.0%, values less robust than those of p15. Despite this difference, it would be interesting to determine whether analyses of p15 and Wilms tumor protein together would provide added benefit over the use of either marker alone.…”
Section: Discussionmentioning
confidence: 50%
“…10 Immunodetection of WT1 in tumor cells has been described in acute leukemia, advanced breast tumors, melanomas, nonsmall cell lung cancer, and genitourinary tract cancer. [11][12][13][14][15][16] WT1 protein has been proposed as a molecular target for cancer immunotherapy. 17,18 Lawley et al 6 studied WT1 expression in 23 vascular tumors and 20 vascular malformations.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, another recent study reported that WT1 expression bears no clinical relevance for colon cancer, lung cancer, or glioblastoma and suggested that the expression of WT1 in cancer cell lines is most likely a result of in-vitro growth conditions of those cells [32]. Perry et al [33], however, found that immunopositivity for WT1 was more commonly seen in primary malignant melanomas (51-83% of cases) than in nonmalignant nevi (7.4-29.6%). WT1 protein is an attractive target antigen for immunotherapy, and different strategies can effectively decrease WT1 expression [34][35][36].…”
Section: Introductionmentioning
confidence: 99%